#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Vascular malformation Subdural haematoma Mantle cell lymphoma Aplastic anaemia Progressive supranuclear palsy Hairy cell leukaemia recurrent Mitochondrial encephalomyopathy Thyroid cancer metastatic Crigler-Najjar syndrome Palmar-plantar erythrodysaesthesia syndrome Chronic hepatitis B Gestational trophoblastic tumour Liver transplant rejection Oesophageal adenocarcinoma Idiopathic intracranial hypertension More trials…

    Learn about Rare Diseases

    Turner’s syndrome Osteosarcoma metastatic Erdheim-Chester disease – Treatment Niemann-Pick disease Pelizaeus-Merzbacher disease – Trials in Disease Chondrosarcoma metastatic – Life with Disease Rhabdomyosarcoma recurrent – Treatment Langerhans’ cell histiocytosis – Treatment Cystic fibrosis – Trials in Disease Andersen-Tawil syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Proline Zinc Acexamate Betula Verrucosa (108) NAVENIBART Eptacog Beta (Activated) Naltrexone Hydrochloride Entinostat TETRODOTOXIN Posaconazole Thiotepa CIRTUVIVINT Bifikafusp Alfa Ammonium Chloride Bp Vsf1.01 Obefazimod Meloxicam AMMONIUM (15N) CHLORIDE Imgn151 20-HYDROXYECDYSONE Sym024 More therapies…

    Learn about Your Condition

    Patent ductus arteriosus Vascular graft thrombosis Aplasia pure red cell Arteriospasm coronary Bacterial prostatitis Hypersensitivity Chronic spontaneous urticaria Orthostatic hypotension Osteoarthritis Chronic myeloid leukaemia Pyoderma Brain abscess Appendicitis perforated B-cell lymphoma refractory Retroperitoneal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • Study on Surgical Treatment with or without Apalutamide for Patients with High-Risk Prostate Cancer Eligible for Radical Prostatectomy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Apalutamide
    Italy

  • Study on the Impact of Exercise and Atorvastatin on Advanced Breast, Ovarian, Prostate, and Kidney Cancer Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Breast cancer metastatic
    • Prostate cancer metastatic
    Investigated Drugs:
    • Atorvastatin
    Finland

  • Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    • Darolutamide
    Austria Belgium Finland France Germany Hungary +5

  • Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Abiraterone
    • Enzalutamide
    • Prednisolone
    Austria Belgium Czechia Denmark Finland France +9

  • Study of Talazoparib and Enzalutamide combination treatment for patients with metastatic prostate cancer who previously received Abiraterone

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Enzalutamide
    • Talazoparib
    France Spain

  • Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-dependent prostate cancer
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Cabazitaxel
    • Capivasertib
    Belgium Denmark Finland Norway Sweden
Previous Page
1 2 3 4 5 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!